US Aptamers Market

ID: MRFR/LS/13114-HCR 100 Pages Satyendra Maurya Last Updated: September 15, 2026
United States Aptamers Market Research Report: Size, Share, Trend Analysis - Growth & Industry Forecast 2025 To 2035
US Aptamers Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)27.82%
2024 Market Size$ 687.62 Million
2025 Market Size$ 878.92 Million
2035 Market Size$ 10,234.04 Million
Key Players
Aptamer Group
SomaLogic
NantOmics
Evoke Bioscience
Aptus Bioreagents
Aptamer Sciences
Trends
  • Rising Demand for Targeted Therapies
  • Advancements in Aptamer Technology
  • Regulatory Support and Clarity
Opportunities
  • Rising Prevalence of Chronic Diseases
  • Growing Interest in Point-of-Care Testing
  • Increasing Investment in Biopharmaceuticals
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Technology (USD Million)
      1. 4.1.1 Systematic Evolution of Ligands by Exponential Enrichment
      2. 4.1.2 SELEX
      3. 4.1.3 Aptamer-based Biosensors
    2. 4.2 Healthcare, BY Application (USD Million)
      1. 4.2.1 Diagnostics
      2. 4.2.2 Therapeutics
      3. 4.2.3 Research Development
      4. 4.2.4 Biomedical
    3. 4.3 Healthcare, BY Type (USD Million)
      1. 4.3.1 DNA Aptamers
      2. 4.3.2 RNA Aptamers
      3. 4.3.3 Xeno-nucleic Acid Aptamers
    4. 4.4 Healthcare, BY End-Use (USD Million)
      1. 4.4.1 Pharmaceutical Industry
      2. 4.4.2 Academic Research
      3. 4.4.3 Biotechnology Companies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Aptamer Group (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 SomaLogic (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 NantOmics (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Evoke Bioscience (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Aptus Bioreagents (IE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Aptamer Sciences (KR)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Base Pair Biotechnologies (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Aptamer Solutions (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TECHNOLOGY
    3. 6.3 US MARKET ANALYSIS BY APPLICATION
    4. 6.4 US MARKET ANALYSIS BY TYPE
    5. 6.5 US MARKET ANALYSIS BY END-USE
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    16. 6.16 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
    18. 6.18 HEALTHCARE, BY END-USE, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY END-USE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Aptamers Market Segmentation

US Aptamers Market By Technology (USD Million, 2025-2035)

  • Systematic Evolution of Ligands by Exponential Enrichment
  • SELEX
  • Aptamer-based Biosensors

US Aptamers Market By Application (USD Million, 2025-2035)

  • Diagnostics
  • Therapeutics
  • Research Development
  • Biomedical

US Aptamers Market By Type (USD Million, 2025-2035)

  • DNA Aptamers
  • RNA Aptamers
  • Xeno-nucleic Acid Aptamers

US Aptamers Market By End-Use (USD Million, 2025-2035)

  • US Aptamers Market Industry
  • Academic Research
  • Biotechnology Companies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.